SCHEMBL4269352

SCHEMBL4269352

Cc1ccc(N)cc1Nc1cccc(-c2cccnc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.69
BCR P11274 7/20 0.69
KARS1 Q15046 2/20 0.58
PRKCA P17252 2/20 0.50
EGFR P00533 3/20 0.49
GAA P10253 1/20 0.49
SRC P12931 1/20 0.49
PRKACA P17612 1/20 0.49
PRKACG P22612 1/20 0.49
PRKACB P22694 1/20 0.49
CYP2A6 P11509 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 1/20 0.47
PDGFRA P16234 3/20 0.47
PDGFRB P09619 2/20 0.47
PSIP1 O75475 1/20 0.44
AXL P30530 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
KIT P10721 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4269273 0.88 ABL1 (0.66) ABL1BCRKARS1PRKCAEGFR
SCHEMBL3565337 0.83 ABL1 (0.66) ABL1BCRKARS1PRKCAGAA
SCHEMBL29555505 0.82 ABL1 (1.00) ABL1BCRPRKCAEGFRSRC
SCHEMBL29366999 0.82 ABL1 (1.00) ABL1BCRPRKCAEGFRSRC
SCHEMBL2392 0.82 ABL1 (1.00) ABL1BCRPRKCAEGFRSRC
SCHEMBL4264785 0.81 KARS1 (0.54) ABL1BCRKARS1PRKCAEGFR
Hydrochloric Acid SCHEMBL2419016 0.81 ABL1 (0.98) ABL1BCRPRKCAEGFRSRC
Ammonia Solution, Strong SCHEMBL4749564 0.81 ABL1 (0.98) ABL1BCRPRKCAEGFRSRC
SCHEMBL14041713 0.80 ABL1 (0.75) ABL1BCRPRKCAEGFRGAA
SCHEMBL2924553 0.79 ABL1 (0.64) ABL1BCRKARS1PRKCAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674901-B2 Process for preparation of imatinib base INSTYTUT FARMACEUTYCZNY (PL) 2010-03-09 US disclosed
US-7674901-B2 Process for preparation of imatinib base INSTYTUT FARMACEUTYCZNY (PL) 2010-03-09 US disclosed
EP-1533304-B1 AMIDE DERIVATIVE NIPPON SHINYAKU CO LTD (JP) 2009-11-04 EP disclosed
US-7494997-B2 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2009-02-24 US disclosed
US-20060014742-A1 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2006-01-19 US disclosed
EP-1533304-A1 AMIDE DERIVATIVE Nippon Shinyaku Co., Ltd. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014742-A1 Amide derivative ABL1, ABL2, BCR ABL1 1/4885BCR 3/4885KARS1 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.